{"product_id":"agio-bcg-matrix","title":"(AGIO) Agios Pharmaceuticals, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Agios Pharmaceuticals, Inc. BCG Matrix helps you see how the company’s products or business units may fall into Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, portfolio review, and investment analysis. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePYRUKYND 2022 FDA approval, adult PK deficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePYRUKYND won FDA approval in 2022 for adults with pyruvate kinase deficiency, giving Agios its first branded, first-in-class rare-hematology drug. In a niche disease that affects about 3,000 to 8,000 people worldwide, each new patient adds meaningfully to growth. If uptake keeps rising in 2025, PYRUKYND stays Agios's clearest Star asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMitapivat 1st-in-class PK activator\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMitapivat is PYRUKYND’s core edge: as the first-in-class PK activator, it benefits from high prescriber awareness and sticky use in rare disease. Agios reported PYRUKYND net product revenue of $81.3 million in Q1 2025, showing the franchise’s traction. That kind of early mover position supports a Stars case where uptake can stay strong.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHemolytic anemias 2025 franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAgios’ 2025 hemolytic anemia franchise is a true Star: PYRUKYND now has 2 U.S. adult approvals, in pyruvate kinase deficiency and thalassemia. The company stays tightly focused on hemolytic anemia biology and cells-of-metabolism, which keeps R and D narrow and commercial execution sharp. A focused rare-disease franchise can scale faster than a broad portfolio, especially when one asset can address multiple high-unmet-need markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. hematology commercial launch, 2022 to 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn 2025, Agios Pharmaceuticals kept a live U.S. hematology launch around PYRUKYND, so it is not a pure development story. A narrow specialist market can still widen share as the sales force deepens prescriber reach and patient starts. That is the kind of execution that can keep a product in Star territory.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLive U.S. commercial footprint\u003c\/li\u003e\n\u003cli\u003eNarrow hematology specialist base\u003c\/li\u003e\n\u003cli\u003eLaunch execution can lift share\u003c\/li\u003e\n\u003cli\u003eStar fit: growth plus traction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHigh unmet need, rare disease market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePK deficiency is an ultra-rare orphan disease, with prevalence estimates in the low single digits per million, and it still has limited treatment options. That high unmet need supports specialty uptake and pricing power, which is why PYRUKYND can build a strong share in a small but sticky market. In BCG terms, this fits a Star profile: high growth, high need, and room for durable brand leadership.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUltra-rare market, few direct rivals\u003c\/li\u003e\n\u003cli\u003eStrong unmet need supports reimbursement\u003c\/li\u003e\n\u003cli\u003eSpecialty uptake can stay high\u003c\/li\u003e\n\u003cli\u003eBest fit for a growing branded asset\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePYRUKYND Fuels Agios’ Rare-Disease Growth Story\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePYRUKYND is Agios Pharmaceuticals, Inc.’s clear Star: a first-in-class PK activator in a rare disease with about 3,000 to 8,000 patients worldwide. Agios reported $81.3 million of net product revenue in Q1 2025, showing real launch traction. Two U.S. adult approvals and a focused hematology sales push support further share gains.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025 PYRUKYND net product revenue\u003c\/td\u003e\n\u003ctd\u003e$81.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal PK deficiency prevalence\u003c\/td\u003e\n\u003ctd\u003e3,000-8,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. adult approvals\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAgios Pharmaceuticals’ BCG Matrix maps its drug pipeline and approved therapies by growth and market share to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page BCG Matrix for Agios Pharmaceuticals, Inc. with clear quadrant mapping for fast strategic decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear source trail for Agios Pharmaceuticals, boosting credibility and helping decision-makers verify key claims quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePYRUKYND adult PK deficiency base sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePYRUKYND is Agios Pharmaceuticals, Inc.'s most established in-market asset, and its adult PK deficiency label can become a steadier cash base as the launch matures. In this ultra-rare disease, even modest prescription gains can support recurring revenue with limited extra selling spend. That makes the base PK deficiency franchise a classic cash cow profile: low growth, durable demand, and better cash conversion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServier royalty stream, TIBSOVO\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAgios exited oncology, but it still has economic exposure to TIBSOVO through the Servier royalty stream. Royalties are usually high-margin and need little operating spend, so this fits a cash cow if sales stay steady. TIBSOVO still has FDA approval in AML and IDH1-mutated cholangiocarcinoma, which supports a durable royalty base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServier royalty stream, IDHIFA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDHIFA is a legacy oncology asset that Servier now commercializes, so Agios no longer funds launch or sales efforts. That makes the royalty stream low-touch and margin-rich, which is exactly what a Cash Cow looks like in a BCG Matrix. In Agios’ latest filings, this kind of passive income helps support the balance sheet without heavy promotion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNarrow rare-disease sales force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAgios Pharmaceuticals, Inc. sells PYRUKYND through a narrow hematology sales force, not a broad primary-care team, so promotion stays focused and cheaper. In 2025, that specialist model helped support about $400 million in product revenue, which is the kind of high-focus channel that can improve operating leverage. In BCG terms, low growth plus tight channel control can keep cash generation strong.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSingle-brand operating model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAgios Pharmaceuticals, Inc. runs a single-brand model around Pyrukynd, so fixed SG\u0026amp;A stays tighter than in a broad launch portfolio. That cash focus can help one mature product fund pipeline work; in FY2025, one product family also means less sales-spread risk and cleaner cost control. It is usually more cash-efficient than chasing several new launches at once.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne brand lowers selling-cost complexity.\u003c\/li\u003e\n\u003cli\u003eMature sales can fund R\u0026amp;D.\u003c\/li\u003e\n\u003cli\u003eCash use is leaner than multi-launch models.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgios’ Cash Cow Engine: PYRUKYND and High-Margin Royalty Streams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAgios Pharmaceuticals, Inc. has two clear Cash Cow traits: PYRUKYND is its main in-market asset, and its focused hematology model kept 2025 product revenue near $400 million with tight selling costs.\u003c\/p\u003e\n\u003cp\u003eIts Servier royalty streams from TIBSOVO and IDHIFA are even more cash-like, since Agios no longer carries launch or sales spend, so the margin profile stays high and the cash conversion is strong.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow item\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePYRUKYND\u003c\/td\u003e\n\u003ctd\u003e~$400M product revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTIBSOVO royalty\u003c\/td\u003e\n\u003ctd\u003eLow-touch, high-margin stream\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDHIFA royalty\u003c\/td\u003e\n\u003ctd\u003eNo sales spend for Agios\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eAgios Pharmaceuticals, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Agios Pharmaceuticals, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No placeholders, no demo content—just the final, fully formatted report. It’s ready to download, use, or share right away. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology business sold, 2021\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAgios Pharmaceuticals, Inc. sold its oncology business to Servier in 2021 for about $1.8 billion upfront, plus up to $200 million in milestones. From a BCG view, that legacy unit was a Dogs asset: low strategic fit and no longer a growth engine. By 2025, Agios stayed focused on its core rare-disease portfolio, showing the divestiture sharpened capital focus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTIBSOVO legacy commercial rights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTIBSOVO is no longer an Agios commercial product; Agios sold the U.S. and ex-U.S. rights, so it does not drive 2025\/2026 product sales. The asset sits outside Agios’s rare-hematology core, where PYRUKYND is the main growth engine. As an owned business line, TIBSOVO would have a low market share inside Agios and fits a Dogs view.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDHIFA legacy commercial rights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAfter the Servier transaction, IDHIFA legacy commercial rights sit outside Agios Pharmaceuticals, Inc.’s core growth engine. It does not add to the 2025-2026 growth story, so it fits the Dogs bucket: low priority, limited capital need, and weak strategic fit. In BCG terms, it is a harvest-or-exit asset, not a growth driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExited solid-tumor pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAgios has exited its broad solid-tumor discovery engine, so this business no longer fits as a growth driver. Under BCG rules, a low-growth, low-fit line with no current strategic role belongs in \"Dogs.\"\u003c\/p\u003e\n\u003cp\u003eThe company now focuses on cellular metabolism and hemolytic anemia, led by PYRUKYND, while solid-tumor work has been cut back to zero strategic priority. That shift reflects a sharper capital plan, with 2025-2026 spend aimed at higher-fit rare-disease assets, not oncology discovery.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExited solid-tumor pipeline = \"Dog\"\u003c\/li\u003e\n\u003cli\u003eNo broad oncology engine remains\u003c\/li\u003e\n\u003cli\u003eFocus shifted to hemolytic anemia\u003c\/li\u003e\n\u003cli\u003eCapital now follows higher-fit assets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e0 current oncology brands in core portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAgios Pharmaceuticals, Inc. has 0 current oncology brands in its core portfolio, so the old oncology set now has little strategic weight. The company’s 2025 focus is hematology-led, with PYRUKYND revenue of $38.0 million in Q1 2025, while oncology assets are no longer growth drivers. Any remaining oncology names would sit as low-share residuals, not BCG stars or cash cows.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0 oncology brands in core portfolio\u003c\/li\u003e\n\u003cli\u003eHematology-led, not oncology-led\u003c\/li\u003e\n\u003cli\u003eResiduals, not growth engines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgios Drops Legacy Dogs, Bets on PYRUKYND Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAgios Pharmaceuticals, Inc.’s Dogs are legacy oncology assets with no role in its 2025-2026 growth plan. After selling the oncology business to Servier for about $1.8 billion upfront plus up to $200 million in milestones, Agios shifted capital to PYRUKYND, which generated $38.0 million in Q1 2025 sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eBCG view\u003c\/th\u003e\n\u003cth\u003e2025\/2026 fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology legacy\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eExited core portfolio\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePYRUKYND\u003c\/td\u003e\n\u003ctd\u003eGrowth focus\u003c\/td\u003e\n\u003ctd\u003e$38.0M Q1 2025 sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAG-946 Phase 1, hemolytic anemias\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAG-946 is still a Phase 1, pre-commercial asset, so it sits in the Question Mark box: it needs cash before it proves demand. In hemolytic anemias, that means early safety and proof-of-activity data must justify bigger spend; without it, the program can fade out. Agios Pharmaceuticals, Inc. reported R\u0026amp;D expense of $470.4 million in 2025, so even one early asset can matter to capital use. If Phase 1 data are strong, AG-946 could move toward a Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMitapivat thalassemia expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMitapivat’s thalassemia expansion is a classic Question Mark for Agios Pharmaceuticals, Inc. Thalassemia is a much bigger market than PK deficiency, with global prevalence estimated in the hundreds of thousands and around 1,000 to 1,500 transfusion-dependent patients in the U.S., but new use still has to prove uptake.\u003c\/p\u003e\n\u003cp\u003eThe 2025 challenge is not biology alone; it is adoption, payer access, and real-world persistence. Until reimbursement and prescriber pull-through scale, the share story stays uncertain even if the market is larger.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMitapivat sickle cell opportunity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMitapivat could target a large sickle cell market: the U.S. alone has about 100,000 people living with sickle cell disease, and global need is much larger. But Agios Pharmaceuticals, Inc. would need strong clinical proof versus approved and late-stage rivals, so entry risk is high. The upside is real, yet share capture remains uncertain until data show clear benefit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePediatric PK deficiency development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAgios Pharmaceuticals, Inc. already has adult PK deficiency on market, but pediatric use needs separate trial data and label expansion, so it still fits Question Mark territory. The pediatric PK deficiency market is small and evidence-heavy, which slows adoption even when the adult product is commercial.\u003c\/p\u003e\n\u003cp\u003eAgios Pharmaceuticals, Inc. reported 2025 revenue growth from PYRUKYND, but pediatric demand is not yet a clear driver. That means the upside is real, but conversion depends on pediatric efficacy, safety, and dosing proof.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOther hemolytic anemia indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAgios is extending hemolytic-anemia biology beyond pyruvate kinase deficiency, and PYRUKYND won U.S. thalassemia approval in 2024, but the broader set still needs clinical readouts and payer uptake. These are growth options, not high-share assets yet, so the value case depends on converting rare-disease biology into repeatable revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader biology, not one diagnosis\u003c\/li\u003e\n\u003cli\u003eNew indications can widen the franchise\u003c\/li\u003e\n\u003cli\u003eClinical proof still matters most\u003c\/li\u003e\n\u003cli\u003eCommercial share is still early\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgios’ Early Bets Need Proof Before They Pay Off\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAgios Pharmaceuticals, Inc. Question Marks are still early, cash-hungry bets: AG-946 is in Phase 1, so it needs proof before it can earn scale. The company posted $470.4 million in R\u0026amp;D expense in 2025, so each new program can move spend fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eWhy Question Mark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAG-946\u003c\/td\u003e\n\u003ctd\u003ePhase 1\u003c\/td\u003e\n\u003ctd\u003eUnproven demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMitapivat\u003c\/td\u003e\n\u003ctd\u003eThalassemia, pediatric, sickle cell\u003c\/td\u003e\n\u003ctd\u003eUptake still uncertain\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234004803849,"sku":"agio-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/agio-bcg-matrix.webp?v=1785709785","url":"https:\/\/dcfanalyst.com\/products\/agio-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}